Trials
4 active
6 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Solid Tumors (2 trials), Renal Insufficiency, Kidney Diseases, Hepatic Insufficiency, Liver Diseases
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).”In the company’s words, NCT07522073 on ClinicalTrials.gov
Other drugs for Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up4
- 1 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 15 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07853040
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 15 Sep 2028 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | |
| Phase 1Recruiting | 1 Jan 2027 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | |
| Phase 1Not yet recruiting | 30 Mar 2027 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis | |
| Phase 1Recruiting | 31 Mar 2027 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment | |
| Phase 1Completed | 29 Sep 2025 | A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants | |
| Phase 1Completed | 15 Oct 2026 | A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026